Statistical analysis plan for the STatin TReatment for COVID-19 to Optimise NeuroloGical recovERy (STRONGER) study: a randomised, open label, controlled trial in subjects with persistent neurological symptoms after COVID-19 infection
Lin, X.; Delfino, C.; Carcel, C.; Munoz-Venturelli, P.; Naismith, S.; Woodward, M.; Peters, R.; Wijesuriya, N.; Law, M.; Harding, I. H.; Wang, X.; Leder, K.; Hutchings, O.; Skiba, M.; Stecher, X.; Zomer, E.; Zoungas, S.; Anderson, C. S.
Show abstract
We outline the statistical analysis plan (SAP) for the STatin TReatment for COVID-19 to Optimise NeuroloGical (STRONGER) study. STRONGER is an international, investigator-initiated and conducted, multicentre, prospective, randomised, open label, blinded endpoint (PROBE) study that aims to determine the safety, efficacy and cost-effectiveness of atorvastatin to improve cognitive function, mood, health-related quality of life, and physical function, in adults with a post-COVID-19 neurological syndrome. Participants are randomised (1:1) to either oral 40 mg atorvastatin for a treatment duration of 12 months (intervention group) or not (control group), on top of usual care. The treatment effect on neuroinflammation in the brain will be assessed by changes on magnetic resonance imaging (MRI) and blood biomarkers.The outcome assessments on participants will be completed in July 2025. The trial is registrated at Clinicaltrials.gov (NCT04904536).
Matching journals
The top 1 journal accounts for 50% of the predicted probability mass.
Similar papers in this journal
- Real-world effects of ACE inhibitors and Angiotensin Receptor Blockers: protocol for an emulation study of the ONTARGET trial using electronic health records 96%
- CATALYST trial protocol: A multicentre, open-label, phase II, multi-arm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults 94%
- Side effect profile and comparative tolerability of newer generation antidepressants in the acute treatment of major depressive disorder in children and adolescents: protocol for a systematic review and network meta-analysis 93%
Similar papers in this journal
- Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): Statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial 95%
- Evaluating Diuretics in Normal Care (EVIDENCE): Protocol of a cluster randomised controlled equivalence trial of prescribing policy to compare the effectiveness of thiazide-type diuretics in hypertension. 93%
- The iHealth-T2D study: Statistical analysis plan for a cluster randomised controlled trial with intensive family-based lifestyle modification programme to reduce type 2 diabetes risk amongst South Asians 93%
Similar papers in this journal
- STIMULATE-ICP: A pragmatic, multi-centre, cluster randomised trial of an integrated care pathway with a nested, Phase III, open label, adaptive platform randomised drug trial in individuals with Long COVID: a structured protocol 96%
- Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer’s disease (BenfoTeam) 94%
- Investigating the use of a one-page infographic to improve recruitment and retention to the BASIL+ Randomised Controlled Trial: A Study Within a Trial (SWAT) 93%
Similar papers in this journal
- Prophylaxis for covid-19: living systematic review and network meta-analysis 93%
- The TARCiS statement: Guidance on terminology, application, and reporting of citation searching 91%
- Vitamin D Supplements for Prevention of Covid-19 or other Acute Respiratory Infections: a Phase 3 Randomized Controlled Trial (CORONAVIT) 91%
Similar papers in this journal
- Tool to assess risk of bias due to missing evidence in network meta-analysis (ROB-MEN): elaboration and examples 94%
- Transparency and reporting characteristics of COVID-19 randomized controlled trials 92%
- Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.